Direct Oral Anticoagulant (DOAC) Reversal
This guideline covers the use of andexanet alfa (Ondexxya®) to reverse rivaroxaban or apixaban in patients with acute, life-threatening G.I. bleeds. It also covers the use of idarucizumab (Praxbind®) to reverse dabigatran in patients with acute, life-threatening bleeds.